Table 1 The basic characteristics of the included studies
No | First author | Year | TNF-α SNPs | Study design | Sample size | Population | SNP genotyping method | HCC etiology | Control | NOQS | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Case (n = 3237) | Control (n = 4843) | ||||||||||
1 | Heneghan | 2004 | -308 G/A, −238 G/A | Case control | 98 | 75 | China | PCR-RFLP | Mixed | Healthy subjects | 8 |
2 | Ho | 2004 | -308 G/A | Case control | 74 | 289 | Taiwan | PCR-RFLP | Mixed | Healthy subjects | 8 |
3 | Migita | 2005 | -308 G/A | Case control | 48 | 188 | Japan | PCR-SSP | HBV | HBV without HCC | 7 |
4 | Niro | 2005 | −1031 T/C, −863 C/A, −308 G/A, −238 G/A | Case control | 30 | 96 | Italy | Sequencing | HBV | SR | 7 |
5 | Jeng | 2007 | −308 G/A | Case control | 108 | 108 | Taiwan | Sequencing | Mixed | Healthy subjects | 9 |
6 | Kummee | 2007 | −863 C/A, −308 G/A, −238 G/A | Case control | 50 | 150 | Thailand | PCR-RFLP | HBV | Healthy subjects | 7 |
7 | Akkiz | 2009 | −308 G/A | Case control | 110 | 110 | Turkey | PCR-RFLP | Mixed | Healthy subjects | 9 |
8 | Wang | 2010 | −308 G/A, −238 G/A | Case control | 230 | 158 | China | Sequencing | HBV | SR | 8 |
9 | Chen | 2011 | −1031 T/C, −863 C/A, −857 C/T, −238 G/A | Case control | 126 | 126 | China | Sequencing | HBV | Healthy subjects | 9 |
10 | Shi | 2011 | −308 G/A | Case control | 88 | 88 | China | PCR-RFLP | HBV | Healthy subjects | 9 |
11 | Qiu | 2012 | −863 C/A, −857 C/T | Case control | 195 | 189 | China | PCR-RFLP | HBV | SR | 7 |
12 | Radwan | 2012 | −308 G/A | Case control | 128 | 160 | Egypt | PCR-RFLP | HCV | Healthy subjects | 8 |
13 | Shi | 2012 | −308 G/A | Case control | 73 | 116 | China | PCR-RFLP | Mixed | Healthy subjects | 8 |
14 | Yang | 2012 | −863 C/A | Case control | 772 | 852 | China | RT-PCR | Mixed | Healthy subjects | 7 |
15 | Teixeira | 2013 | −308 G/A, −238 G/A | Case control | 111 | 202 | Brazil | PCR-SSP | Mixed | Healthy subjects | 5 |
16 | Panigrahi | 2014 | −863 C/A, −857 C/T, −238 G/A | Case control | 14 | 85 | India | PCR-RFLP | HBV | Healthy subjects | 6 |
17 | Saxena | 2014 | −308 G/A | Case control | 59 | 139 | India | PCR-RFLP | HBV | Healthy subjects | 8 |
18 | Jin | 2015 | −1031 T/C, −857 C/T, −238 G/A | Case control | 224 | 206 | Korea | Single base primer extension assay | HBV | LC | 7 |
19 | Sghaier | 2015 | −308 G/A, −238 G/A | Case control | 15 | 200 | Tunisia | PCR-RFLP | HBV | Healthy subjects | 8 |
20 | Shin | 2015 | −1031 T/C, −863 C/A, −857 C/T, −308 G/A, −238 G/A | Case control | 157 | 201 | Korea | PCR-RFLP | Mixed | Healthy subjects | 8 |
21 | Yang | 2015 | −1031 T/C, −863 C/A, −857 C/T, −308 G/A | Case control | 298 | 889 | Taiwan | PCR-RFLP | Smoking and alcohol | Healthy subjects | 7 |
22 | Tsai | 2017 | −308 G/A | Case control | 200 | 200 | Taiwan | Sequencing | HBV | LC | 6 |
23 | Tharwat | 2018 | −308 G/A | Retrospective cohort | 29 | 16 | Egypt | PCR-RFLP | HCV | Healthy subjecys | 8 |